Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNDO-109-Activated NK Cells in High Risk AML
NCT01520558Phase 2Unknown
- Sponsor
- Fortress Biotech
- Start
- Dec 2012
- Primary completion
- Mar 2016
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CNDO-109 in acute myeloid leukemia (AML), sponsored by Fortress Biotech. Status: unknown.
02
Drugs
CNDO-109
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01520558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01520558.